Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES)-Reference-Cited by-同舟云学术

Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES)

Published:2019-04-01 Issue:1 Volume:19 Page:
ISSN:1471-2261
Container-title:BMC Cardiovascular Disorders
language:en
Short-container-title:BMC Cardiovasc Disord

Author:

Kennel Peter J.,Kneifati-Hayek Jerard,Bryan Joanna,Banerjee Samprit,Sobol Irina,Lachs Mark S.,Safford Monika M.,Goyal Parag^ORCID

Funder

National Institute on Aging

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12872-019-1058-7.pdf

Reference32 articles.

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128(16):1810–52.

2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017.

3. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–43.

4. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226–33.

5. Chong VH, Singh J, Parry H, Saunders J, Chowdhury F, Mancini DM, Lang CC. Management of Noncardiac Comorbidities in chronic heart failure. Cardiovasc Ther. 2015;33(5):300–15.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Economic Burden of Heart Failure with Reduced Ejection Fraction;Heart Failure Clinics;2024-10

2. Polypharmacy and Guideline-Directed Medical Therapy Initiation Among Adults Hospitalized With Heart Failure;JACC: Advances;2024-09

3. Analysis of longitudinal patterns and predictors of medicine use in residential aged care using group‐based trajectory modelling: The MEDTRAC‐Polypharmacy longitudinal cohort study;British Journal of Clinical Pharmacology;2024-08-25

4. Trends in polypharmacy among U.S. adults with asthma, 2001–2020;Journal of Asthma;2024-08-23

5. Impact of hyper-polypharmacy due to non-cardiovascular medications on long-term clinical outcomes following endovascular treatment for lower limb artery disease: A sub-analysis of the I-PAD Nagano registry;Journal of Cardiology;2024-07